IRIS Accounts Production v24.3.0.553 03707271 director 1.3.23 29.2.24 29.2.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh037072712023-02-28037072712024-02-29037072712023-03-012024-02-29037072712022-02-28037072712022-03-012023-02-28037072712023-02-2803707271ns15:EnglandWales2023-03-012024-02-2903707271ns14:PoundSterling2023-03-012024-02-2903707271ns10:Director12023-03-012024-02-2903707271ns10:PrivateLimitedCompanyLtd2023-03-012024-02-2903707271ns10:SmallEntities2023-03-012024-02-2903707271ns10:AuditExempt-NoAccountantsReport2023-03-012024-02-2903707271ns10:SmallCompaniesRegimeForDirectorsReport2023-03-012024-02-2903707271ns10:SmallCompaniesRegimeForAccounts2023-03-012024-02-2903707271ns10:FullAccounts2023-03-012024-02-290370727112023-03-012024-02-2903707271ns10:CompanySecretary12023-03-012024-02-2903707271ns10:RegisteredOffice2023-03-012024-02-2903707271ns5:CurrentFinancialInstruments2024-02-2903707271ns5:CurrentFinancialInstruments2023-02-2803707271ns5:ShareCapital2024-02-2903707271ns5:ShareCapital2023-02-2803707271ns5:RetainedEarningsAccumulatedLosses2024-02-2903707271ns5:RetainedEarningsAccumulatedLosses2023-02-2803707271ns5:NetGoodwill2023-03-012024-02-2903707271ns5:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2903707271ns5:LeaseholdImprovements2023-03-012024-02-2903707271ns5:FurnitureFittings2023-03-012024-02-2903707271ns5:ComputerEquipment2023-03-012024-02-2903707271ns5:NetGoodwill2023-02-2803707271ns5:NetGoodwill2024-02-2903707271ns5:NetGoodwill2023-02-2803707271ns5:ShortLeaseholdAssetsns5:LandBuildings2023-02-2803707271ns5:LeaseholdImprovements2023-02-2803707271ns5:FurnitureFittings2023-02-2803707271ns5:ComputerEquipment2023-02-2803707271ns5:ShortLeaseholdAssetsns5:LandBuildings2023-03-012024-02-2903707271ns5:ShortLeaseholdAssetsns5:LandBuildings2024-02-2903707271ns5:LeaseholdImprovements2024-02-2903707271ns5:FurnitureFittings2024-02-2903707271ns5:ComputerEquipment2024-02-2903707271ns5:ShortLeaseholdAssetsns5:LandBuildings2023-02-2803707271ns5:LeaseholdImprovements2023-02-2803707271ns5:FurnitureFittings2023-02-2803707271ns5:ComputerEquipment2023-02-2803707271ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-02-2903707271ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-02-28
REGISTERED NUMBER: 03707271 (England and Wales)















Unaudited Financial Statements for the Year Ended 29 February 2024

for

EVERGREEN PHARMA LIMITED

EVERGREEN PHARMA LIMITED (Registered number: 03707271)






Contents of the Financial Statements
for the Year Ended 29 February 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


EVERGREEN PHARMA LIMITED

Company Information
for the Year Ended 29 February 2024







DIRECTOR: Miss S Ekjan





SECRETARY: Mr I Ekjan





REGISTERED OFFICE: 6 Greenway
London
N14 6NN





REGISTERED NUMBER: 03707271 (England and Wales)





ACCOUNTANTS: Soneji & Co Ltd
20 egerton Close,
Pinner
Middlesex
HA5 2LP

EVERGREEN PHARMA LIMITED (Registered number: 03707271)

Balance Sheet
29 February 2024

29.2.24 28.2.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 - 650
- 650

CURRENT ASSETS
Stocks 22,631 20,219
Debtors 6 86,593 63,895
Cash at bank and in hand 111,272 135,219
220,496 219,333
CREDITORS
Amounts falling due within one year 7 94,693 107,967
NET CURRENT ASSETS 125,803 111,366
TOTAL ASSETS LESS CURRENT
LIABILITIES

125,803

112,016

CAPITAL AND RESERVES
Called up share capital 2 2
Retained earnings 125,801 112,014
SHAREHOLDERS' FUNDS 125,803 112,016

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 29 February 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 29 February 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 22 November 2024 and were signed by:



Miss S Ekjan - Director


EVERGREEN PHARMA LIMITED (Registered number: 03707271)

Notes to the Financial Statements
for the Year Ended 29 February 2024

1. STATUTORY INFORMATION

EVERGREEN PHARMA LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2000, is being amortised evenly over its estimated useful life of twenty years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 5% on cost
Fixtures and fittings - 20% on cost
Computer equipment - 100% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

EVERGREEN PHARMA LIMITED (Registered number: 03707271)

Notes to the Financial Statements - continued
for the Year Ended 29 February 2024

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 5 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 March 2023
and 29 February 2024 22,000
AMORTISATION
At 1 March 2023
and 29 February 2024 22,000
NET BOOK VALUE
At 29 February 2024 -
At 28 February 2023 -

5. TANGIBLE FIXED ASSETS
Improvements Fixtures
Short to and Computer
leasehold property fittings equipment Totals
£    £    £    £    £   
COST
At 1 March 2023
and 29 February 2024 2,550 13,000 56,212 6,944 78,706
DEPRECIATION
At 1 March 2023 2,550 12,350 56,212 6,944 78,056
Charge for year - 650 - - 650
At 29 February 2024 2,550 13,000 56,212 6,944 78,706
NET BOOK VALUE
At 29 February 2024 - - - - -
At 28 February 2023 - 650 - - 650

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
29.2.24 28.2.23
£    £   
Trade debtors 46,761 38,454
Other debtors 39,832 25,441
86,593 63,895

EVERGREEN PHARMA LIMITED (Registered number: 03707271)

Notes to the Financial Statements - continued
for the Year Ended 29 February 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
29.2.24 28.2.23
£    £   
Trade creditors 59,264 56,840
Taxation and social security 3,386 8,485
Other creditors 32,043 42,642
94,693 107,967

8. RELATED PARTY DISCLOSURES

The company was under the control of Miss Ekjan throughout the current and previous year. Miss Ekjan is the managing director and only shareholder.

The company entered in to a new lease for twenty years on April 2004 where Miss Ekjan and partners owns the freehold. During the year company paid a rent of £33,600 (2023 - £33,600) in respect of this.

During the year the company has paid salary of £97,200 (2023 - £97,200) to Miss Ekjan.

No other transactions with related parties were undertaken such as are required to be disclosed under Financial Reporting Standard 8.